Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

Treatment tested

• Interferon beta-1b

  Interferon alpha/beta receptor agonist

• BETACONNECT device

Other measures (1)

Inclusion Criteria: * Male and females greater than or equal to 18 years of age * Diagnosis of RRMS according to revised McDonald Criteria (2010) or (CIS) * Prescribed BETASERON (note: decision to treat with BETASERON must be made independent of participation in this study) * Confirmation of insurance coverage for BETASERON treatment * Access to a personal computer to complete online patient satisfaction survey at Week 6 Exclusion Criteria: * Currently enrolled in a clinical trial or other observational study for Multiple Sclerosis treatment * Documented substance abuse within the previous 6 months prior to study enrollment * Any major laboratory value abnormality that the investigator believes would preclude the patient from participating in the study * Any medical disorder, condition or history that in the opinion of the investigator would impair the patient's ability to participate in or complete the study * Pregnant or nursing

The primary objective of this study is to assess adherence and persistence to BETASERON therapy in patients who are using the BETACONNECT auto-injector device (BETACONNECT device). The secondary objective of this study is to assess patient-reported satisfaction with the BETACONNECT device.